{"hands_on_practices": [{"introduction": "Type A adverse reactions are fundamentally linked to drug exposure. This exercise demonstrates the core pharmacokinetic principle that a change in drug clearance, such as from renal impairment, directly alters the total drug exposure ($AUC$) and consequently modifies the risk of dose-dependent toxicity. By working through this calculation, you will practice a crucial skill used in clinical pharmacology to predict and prevent Type A reactions through dose adjustment. [@problem_id:4995624]", "problem": "A single oral dose of a renally cleared drug is administered to a patient. Assume a one-compartment, linear pharmacokinetic system in which bioavailability $F$ and total clearance $CL_{\\text{tot}}$ determine the exposure. The Area Under the plasma Concentration–time curve (AUC) is defined as the time integral of concentration following the dose. Clearance is defined as the volume of plasma from which drug is completely removed per unit time, and total clearance is the sum of organ clearances. Consider the following scenario:\n\n- Bioavailability $F=0.60$.\n- Administered dose $\\text{Dose}=150\\,\\mathrm{mg}$.\n- Baseline total clearance $CL_{\\text{tot}}=12\\,\\mathrm{L\\cdot h^{-1}}$.\n- The drug’s renal clearance fraction is $f_{r}=0.75$, so $CL_{\\text{ren}}=f_{r}\\,CL_{\\text{tot}}$ and $CL_{\\text{hep}}=(1-f_{r})\\,CL_{\\text{tot}}$.\n- Due to renal impairment, renal clearance decreases by a factor $k=3$ (with $k>1$), while hepatic clearance remains unchanged.\n\nUsing the fundamental definitions above, derive the impaired total clearance and compute:\n1) the impaired exposure $AUC_{\\text{imp}}$, expressed in $\\mathrm{mg\\cdot h\\cdot L^{-1}}$; and\n2) the fold-change in the risk of Type A (augmented, dose/exposure-dependent) adverse drug reactions relative to baseline, under the assumption that the risk in the clinically relevant range is directly proportional to $AUC$.\n\nRound both numerical results to three significant figures. Provide your final answer as the ordered pair $\\left(AUC_{\\text{imp}}, \\text{fold-change}\\right)$.", "solution": "The problem is assessed to be valid as it is scientifically grounded in fundamental principles of pharmacokinetics, well-posed with a complete and consistent set of data, and objective in its language and definitions. The scenario describes a standard clinical-pharmacological problem that can be formalized and solved rigorously.\n\nThe fundamental relationship governing exposure for a drug administered orally in a linear, one-compartment system is given by:\n$$\nAUC = \\frac{F \\cdot \\text{Dose}}{CL_{\\text{tot}}}\n$$\nwhere $AUC$ is the Area Under the plasma Concentration-time curve, $F$ is the bioavailability, $\\text{Dose}$ is the administered dose, and $CL_{\\text{tot}}$ is the total systemic clearance.\n\nTotal clearance is the sum of the clearances by individual organs. In this case, it is the sum of renal clearance ($CL_{\\text{ren}}$) and hepatic clearance ($CL_{\\text{hep}}$):\n$$\nCL_{\\text{tot}} = CL_{\\text{ren}} + CL_{\\text{hep}}\n$$\n\nFirst, we establish the baseline pharmacokinetic parameters.\nThe given baseline values are:\n- Administered dose, $\\text{Dose} = 150\\,\\mathrm{mg}$\n- Bioavailability, $F = 0.60$\n- Baseline total clearance, $CL_{\\text{tot,base}} = 12\\,\\mathrm{L\\cdot h^{-1}}$\n- Renal clearance fraction, $f_{r} = 0.75$\n\nUsing these, we can calculate the baseline component clearances.\nThe baseline renal clearance is:\n$$\nCL_{\\text{ren,base}} = f_{r} \\cdot CL_{\\text{tot,base}} = 0.75 \\cdot 12\\,\\mathrm{L\\cdot h^{-1}} = 9\\,\\mathrm{L\\cdot h^{-1}}\n$$\nThe baseline hepatic clearance is:\n$$\nCL_{\\text{hep,base}} = (1 - f_{r}) \\cdot CL_{\\text{tot,base}} = (1 - 0.75) \\cdot 12\\,\\mathrm{L\\cdot h^{-1}} = 0.25 \\cdot 12\\,\\mathrm{L\\cdot h^{-1}} = 3\\,\\mathrm{L\\cdot h^{-1}}\n$$\nAs a check, $CL_{\\text{ren,base}} + CL_{\\text{hep,base}} = 9\\,\\mathrm{L\\cdot h^{-1}} + 3\\,\\mathrm{L\\cdot h^{-1}} = 12\\,\\mathrm{L\\cdot h^{-1}} = CL_{\\text{tot,base}}$, which is correct.\n\nNext, we consider the state of renal impairment. The problem states that renal clearance decreases by a factor $k=3$, while hepatic clearance remains unchanged.\nThe impaired renal clearance, $CL_{\\text{ren,imp}}$, is:\n$$\nCL_{\\text{ren,imp}} = \\frac{CL_{\\text{ren,base}}}{k} = \\frac{9\\,\\mathrm{L\\cdot h^{-1}}}{3} = 3\\,\\mathrm{L\\cdot h^{-1}}\n$$\nThe impaired hepatic clearance is unchanged:\n$$\nCL_{\\text{hep,imp}} = CL_{\\text{hep,base}} = 3\\,\\mathrm{L\\cdot h^{-1}}\n$$\nThe impaired total clearance, $CL_{\\text{tot,imp}}$, is the sum of the new component clearances:\n$$\nCL_{\\text{tot,imp}} = CL_{\\text{ren,imp}} + CL_{\\text{hep,imp}} = 3\\,\\mathrm{L\\cdot h^{-1}} + 3\\,\\mathrm{L\\cdot h^{-1}} = 6\\,\\mathrm{L\\cdot h^{-1}}\n$$\nThis completes the derivation of the impaired total clearance.\n\nNow, we can compute the two requested quantities.\n\n1) The impaired exposure, $AUC_{\\text{imp}}$, is calculated using the fundamental exposure equation with the impaired total clearance. The dose and bioavailability are assumed to be unaffected by the change in clearance.\n$$\nAUC_{\\text{imp}} = \\frac{F \\cdot \\text{Dose}}{CL_{\\text{tot,imp}}} = \\frac{0.60 \\cdot 150\\,\\mathrm{mg}}{6\\,\\mathrm{L\\cdot h^{-1}}} = \\frac{90\\,\\mathrm{mg}}{6\\,\\mathrm{L\\cdot h^{-1}}} = 15\\,\\mathrm{mg\\cdot h\\cdot L^{-1}}\n$$\nRounding to three significant figures, $AUC_{\\text{imp}} = 15.0\\,\\mathrm{mg\\cdot h\\cdot L^{-1}}$.\n\n2) The fold-change in the risk of Type A adverse drug reactions. The problem states that this risk is directly proportional to $AUC$. Let $\\text{Risk}$ be the risk and $c$ be the constant of proportionality.\n$$\n\\text{Risk} = c \\cdot AUC\n$$\nThe fold-change in risk is the ratio of the impaired risk to the baseline risk:\n$$\n\\text{Fold-change} = \\frac{\\text{Risk}_{\\text{imp}}}{\\text{Risk}_{\\text{base}}} = \\frac{c \\cdot AUC_{\\text{imp}}}{c \\cdot AUC_{\\text{base}}} = \\frac{AUC_{\\text{imp}}}{AUC_{\\text{base}}}\n$$\nThis ratio can be expressed in terms of clearances:\n$$\n\\frac{AUC_{\\text{imp}}}{AUC_{\\text{base}}} = \\frac{F \\cdot \\text{Dose} / CL_{\\text{tot,imp}}}{F \\cdot \\text{Dose} / CL_{\\text{tot,base}}} = \\frac{CL_{\\text{tot,base}}}{CL_{\\text{tot,imp}}}\n$$\nSubstituting the calculated clearance values:\n$$\n\\text{Fold-change} = \\frac{12\\,\\mathrm{L\\cdot h^{-1}}}{6\\,\\mathrm{L\\cdot h^{-1}}} = 2\n$$\nRounding to three significant figures, the fold-change is $2.00$.\n\nThe final answer is the ordered pair $\\left(AUC_{\\text{imp}}, \\text{fold-change}\\right)$, which is $\\left(15.0\\,\\mathrm{mg\\cdot h\\cdot L^{-1}}, 2.00\\right)$.", "answer": "$$\n\\boxed{\\begin{pmatrix} 15.0 & 2.00 \\end{pmatrix}}\n$$", "id": "4995624"}, {"introduction": "The classification of an adverse reaction can sometimes seem nuanced, especially when genetic factors are involved. This problem explores the case of azathioprine toxicity, a classic example of how a pharmacogenetic trait can drastically increase susceptibility to a Type A reaction. This practice will challenge you to understand that \"predictable\" refers to the underlying mechanism of action, which remains the same even when an individual's unique genetics alter their pharmacokinetic profile. [@problem_id:4995591]", "problem": "A patient with inflammatory bowel disease begins azathioprine therapy at a standard weight-based dose. Within $10$ days, the patient develops severe neutropenia. Laboratory evaluation shows red blood cell (RBC) thioguanine nucleotide concentration of $980$ pmol per $8\\times 10^{8}$ RBC, which exceeds the usual therapeutic range of $235$ to $450$ pmol per $8\\times 10^{8}$ RBC. Genetic testing reveals homozygous deficiency in Thiopurine S-methyltransferase (TPMT). Azathioprine is a prodrug of $6$-mercaptopurine ($6$-MP), which is converted to thioguanine nucleotides that incorporate into deoxyribonucleic acid (DNA), preferentially affecting rapidly dividing cells. TPMT catalyzes methylation of thiopurines, reducing formation of active thioguanine nucleotide species.\n\nUsing foundational pharmacokinetic and pharmacodynamic definitions and laws, including the concept that steady-state concentration depends on formation and elimination processes and that pharmacologic effect is related to concentration via a monotonic concentration–effect relationship, decide which option best explains why this myelosuppression is a predictably augmented on-target effect and therefore appropriately classified as a Type A adverse drug reaction, despite interindividual genetic heterogeneity in TPMT activity.\n\nA. TPMT deficiency reduces inactivation of thiopurines, increasing active metabolite concentration $C$ for a given dose, which raises pharmacologic effect $E(C)$ on all rapidly dividing cells according to the same mechanism as intended immunosuppression; the dose–response remains monotonic and predictable (e.g., higher $C$ yields greater marrow suppression), so this is Type A. Genetic polymorphism shifts parameters such as clearance and sensitivity but does not alter mechanism, preserving predictability.\n\nB. The severe neutropenia is Type B because it is an idiosyncratic hypersensitivity reaction that is independent of dose and unrelated to active metabolite concentration; genetic testing does not meaningfully predict risk.\n\nC. Bone marrow suppression is off-target because azathioprine is intended to affect lymphocytes only; effects on hematopoietic progenitors arise from a distinct mechanism, making the reaction Type B.\n\nD. TPMT deficiency converts azathioprine into a novel metabolite not formed in typical patients, so the effect cannot be predicted by concentration–effect principles; therefore, it must be Type B rather than Type A.\n\nE. The reaction is mixed Type A/Type B because TPMT deficiency simultaneously causes dose-dependent toxicity and immune-mediated rash, and mixed mechanisms cannot be classified as Type A even if concentration predicts severity.", "solution": "The problem statement provides a clinical scenario and asks for an explanation based on foundational pharmacological principles.\n\n**Problem Statement Validation**\n\n*   **Step 1: Extract Givens**\n    *   Patient with inflammatory bowel disease is treated with azathioprine at a standard weight-based dose.\n    *   Within $10$ days, the patient develops severe neutropenia.\n    *   Red blood cell (RBC) thioguanine nucleotide (TGN) concentration is measured at $980$ pmol per $8\\times 10^{8}$ RBC.\n    *   The usual therapeutic range for TGN is $235$ to $450$ pmol per $8\\times 10^{8}$ RBC.\n    *   Genetic testing reveals homozygous deficiency in Thiopurine S-methyltransferase (TPMT).\n    *   Azathioprine is a prodrug of $6$-mercaptopurine ($6$-MP).\n    *   $6$-MP is converted to active TGNs, which incorporate into DNA, affecting rapidly dividing cells.\n    *   TPMT catalyzes the methylation (inactivation) of thiopurines, reducing the formation of active TGNs.\n    *   The question requires using the principles that steady-state concentration depends on formation and elimination, and that pharmacologic effect, $E$, is a monotonic function of concentration, $C$, (i.e., $E(C)$) to explain why the adverse reaction is Type A.\n\n*   **Step 2: Validate Using Extracted Givens**\n    *   **Scientifically Grounded:** The problem is based on well-established principles of pharmacogenetics and pharmacology. The mechanism of azathioprine, the role of TPMT, and the resulting clinical toxicity in deficient individuals are textbook examples. The data provided (TGN levels, timeline) are clinically realistic.\n    *   **Well-Posed:** The problem is clearly stated. It provides all necessary information and a guiding framework (PK/PD principles) to arrive at a logical explanation for the classification of the adverse drug reaction (ADR).\n    *   **Objective:** The language is clinical, precise, and free of subjective or ambiguous terminology.\n\n*   **Step 3: Verdict and Action**\n    *   The problem statement is valid. It is scientifically sound, well-posed, and objective. I will proceed with the solution.\n\n**Derivation of Solution**\n\nAdverse drug reactions are broadly classified. The primary distinction is between Type A (Augmented) and Type B (Bizarre or Idiosyncratic) reactions.\n\n1.  **Type A (Augmented) reactions** are predictable from the known pharmacology of a drug. They are dose-dependent and represent an exaggeration of the drug's intended therapeutic effect or known side effects. The mechanism is the same as the drug's primary action.\n\n2.  **Type B (Bizarre) reactions** are not predictable from the drug's known pharmacology. They are typically not dose-dependent in a simple monotonic fashion and are often caused by unusual patient-specific factors, such as immunological responses (e.g., allergies) or the formation of reactive metabolites via atypical pathways.\n\nWe must analyze the given scenario using the provided pharmacokinetic (PK) and pharmacodynamic (PD) principles.\n\n**Pharmacokinetic (PK) Analysis:**\nThe concentration of active metabolites (TGNs) at steady state depends on the balance between their formation and elimination. The problem states that azathioprine is administered at a \"standard dose,\" which provides a certain rate of formation of its downstream metabolite, $6$-MP. The metabolism of $6$-MP proceeds via two main competing routes:\n*   Anabolic pathway: Conversion by HPRT to active TGNs.\n*   Catabolic pathway: Inactivation by TPMT to methylated metabolites.\n\nIn this patient, a homozygous TPMT deficiency means the primary inactivation pathway is non-functional. Consequently, the metabolism of $6$-MP is shunted almost entirely down the anabolic pathway. This leads to a drastically increased rate of formation and accumulation of the active TGNs. The patient's TGN level of $980$ pmol per $8\\times 10^{8}$ RBC, which is over twice the upper limit of the therapeutic range ($450$ pmol per $8\\times 10^{8}$ RBC), quantitatively confirms this severe overproduction of the active metabolite. In essence, the genetic deficiency fundamentally alters the drug's clearance, leading to supratherapeutic concentrations despite a standard administered dose.\n\n**Pharmacodynamic (PD) Analysis:**\nThe problem states that TGNs exert their effect by incorporating into DNA, which preferentially affects rapidly dividing cells. This is the intended mechanism for immunosuppression (targeting lymphocytes in IBD). It is also the mechanism for myelosuppression (targeting hematopoietic progenitor cells in the bone marrow). Therefore, the therapeutic effect and the adverse effect share the exact same mechanism of action.\nThe problem also instructs us to assume a monotonic concentration-effect relationship, $E(C)$. This implies that as the concentration $C$ of TGNs increases, the effect $E$ (cytotoxicity) also increases. The patient's extremely high TGN concentration predictably leads to an exaggerated pharmacological effect—in this case, severe cytotoxicity affecting the bone marrow, resulting in neutropenia.\n\n**Conclusion on ADR Classification:**\nThe neutropenia is a direct, concentration-dependent consequence of the drug's primary mechanism of action. The effect is an *augmentation* or exaggeration of the known pharmacology of thiopurines. The genetic polymorphism in TPMT makes the patient highly susceptible, but it does so by altering the drug's PK in a predictable manner. If one knows the patient's TPMT status, this severe toxicity is not \"bizarre\" or \"unpredictable\"; it is an expected outcome of standard dosing. Thus, it is correctly classified as a **Type A** reaction.\n\n**Option-by-Option Analysis**\n\n**A. TPMT deficiency reduces inactivation of thiopurines, increasing active metabolite concentration $C$ for a given dose, which raises pharmacologic effect $E(C)$ on all rapidly dividing cells according to the same mechanism as intended immunosuppression; the dose–response remains monotonic and predictable (e.g., higher $C$ yields greater marrow suppression), so this is Type A. Genetic polymorphism shifts parameters such as clearance and sensitivity but does not alter mechanism, preserving predictability.**\nThis option accurately synthesizes the PK and PD reasoning. It correctly identifies that TPMT deficiency reduces inactivation, leading to higher concentration ($C$) of the active metabolite. It correctly states this higher $C$ produces a greater effect ($E(C)$) based on a monotonic relationship. It correctly notes that the mechanism for the adverse effect (marrow suppression) is the same as the therapeutic effect (immunosuppression). Finally, it correctly concludes this is a Type A reaction and that the genetic factor alters PK parameters without changing the fundamental, predictable nature of the drug's action.\n**Verdict: Correct.**\n\n**B. The severe neutropenia is Type B because it is an idiosyncratic hypersensitivity reaction that is independent of dose and unrelated to active metabolite concentration; genetic testing does not meaningfully predict risk.**\nThis option contains several falsehoods. The mechanism is cytotoxic, not hypersensitivity. The reaction is highly dependent on the active metabolite concentration, as shown by the lab data. Genetic testing for TPMT is a critical tool precisely because it *does* meaningfully predict the risk of this very reaction.\n**Verdict: Incorrect.**\n\n**C. Bone marrow suppression is off-target because azathioprine is intended to affect lymphocytes only; effects on hematopoietic progenitors arise from a distinct mechanism, making the reaction Type B.**\nThis is incorrect. The mechanism of action—cytotoxicity in rapidly dividing cells—is the same for both lymphocytes and hematopoietic progenitors. An effect resulting from the intended mechanism, even if it occurs in an unintended tissue, is considered an extension of the on-target pharmacology, characteristic of a Type A reaction. It is not a distinct mechanism.\n**Verdict: Incorrect.**\n\n**D. TPMT deficiency converts azathioprine into a novel metabolite not formed in typical patients, so the effect cannot be predicted by concentration–effect principles; therefore, it must be Type B rather than Type A.**\nThis is factually incorrect. TPMT deficiency does not create a novel metabolite; it leads to an overabundance of the *normal* active metabolites (TGNs) by blocking an inactivation pathway. The effect is perfectly predictable from concentration-effect principles; the observed high concentration predicts the severe toxicity.\n**Verdict: Incorrect.**\n\n**E. The reaction is mixed Type A/Type B because TPMT deficiency simultaneously causes dose-dependent toxicity and immune-mediated rash, and mixed mechanisms cannot be classified as Type A even if concentration predicts severity.**\nThis option introduces information not present in the problem statement (an \"immune-mediated rash\"). The analysis must be confined to the given data, which only mentions neutropenia. The neutropenia itself is a classic Type A reaction. The claim that \"mixed mechanisms cannot be classified as Type A\" is an oversimplification and irrelevant here, as we are classifying a specific adverse event (neutropenia) whose mechanism is clearly Type A.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4995591"}, {"introduction": "Unlike Type A reactions, Type B reactions are not predictable from a drug's primary pharmacology and often involve complex immune responses. This exercise uses the example of Heparin-Induced Thrombocytopenia (HIT) type II to illustrate the nature of a Type B reaction. You will apply Bayes' theorem to see how clinicians use diagnostic test results to update their assessment of risk, a vital skill for managing these unpredictable adverse events. [@problem_id:4995652]", "problem": "A hospitalized patient receiving unfractionated heparin develops a platelet count drop on day $6$ of therapy with no other clear cause. Heparin-induced thrombocytopenia (HIT) type II is suspected. Use the following foundational facts to guide your reasoning: Type A adverse drug reactions are dose-dependent, predictable from a drug’s primary pharmacology, and common; Type B adverse drug reactions are not dose-dependent, are uncommon, and are often immune-mediated and unpredictable. The patient’s pre-test probability of true HIT type II, estimated from a validated clinical scoring system, is $0.20$. A platelet factor $4$ (PF4; platelet factor $4$)/heparin antibody Enzyme-Linked Immunosorbent Assay (ELISA) is performed and returns positive. For this ELISA in the relevant setting, the sensitivity is $0.97$ and the specificity is $0.80$.\n\nStarting only from the definitions of adverse drug reaction types and from the axiomatic definition of conditional probability, do the following:\n- Decide whether HIT type II should be classified as a Type A or Type B adverse drug reaction and justify your choice using the given definitions.\n- Then, using Bayes’ theorem as derived from the definition of conditional probability and the definitions of sensitivity and specificity, compute the post-test probability that the patient truly has HIT type II given the positive PF4/heparin ELISA.\n\nExpress the final post-test probability as a decimal and round your answer to four significant figures.", "solution": "The problem is assessed to be scientifically grounded, well-posed, and internally consistent. It presents a standard clinical reasoning scenario that requires both conceptual classification and quantitative analysis using established principles of pharmacology and statistics. All necessary data are provided.\n\nThe solution proceeds in two parts as requested by the problem statement.\n\nPart 1: Classification of Heparin-Induced Thrombocytopenia (HIT) Type II\n\nThe problem provides definitions for two types of adverse drug reactions (ADRs):\n- **Type A**: dose-dependent, predictable from the drug's primary pharmacology, and common.\n- **Type B**: not dose-dependent, uncommon, often immune-mediated, and unpredictable.\n\nThe problem describes a patient suspected of having HIT type II, a known complication of heparin therapy. The a priori probability of this condition is given as $0.20$, which is relatively low, suggesting it is an \"uncommon\" event. More critically, the diagnostic test mentioned is a \"platelet factor $4$ (PF4)/heparin antibody Enzyme-Linked Immunosorbent Assay (ELISA)\". The explicit reference to an \"antibody\" test confirms that the underlying pathophysiology is immune-mediated. In HIT type II, antibodies form against the complex of heparin and platelet factor $4$. This immune response is not a direct extension of heparin's primary pharmacological action, which is anticoagulation via potentiation of antithrombin.\n\nLet us compare the features of HIT type II with the provided definitions:\n- **Dose-dependence**: Immune-mediated reactions are typically not dose-dependent in a linear fashion, as a sufficient antigenic stimulus, which can be small, is enough to trigger the immune cascade. Thus, HIT type II is generally considered not dose-dependent.\n- **Predictability/Pharmacology**: The reaction is not a predictable extension of heparin's anticoagulant effect. Instead, it is a paradoxical prothrombotic condition mediated by an idiosyncratic immune response. It is therefore \"unpredictable\" and not related to the drug's primary pharmacology.\n- **Prevalence**: HIT type II is an \"uncommon\" reaction.\n- **Mechanism**: The condition is \"immune-mediated,\" as confirmed by the formation of PF4/heparin antibodies.\n\nBased on this analysis, HIT type II aligns perfectly with the definition of a Type B adverse drug reaction. It is an uncommon, unpredictable, immune-mediated reaction that is not dose-dependent in the typical sense and is not an extension of the drug's primary pharmacological effect.\n\nPart 2: Calculation of the Post-Test Probability\n\nWe are asked to compute the post-test probability of the patient having HIT type II given a positive ELISA result. This requires the use of Bayes' theorem, which we will derive from the axiomatic definition of conditional probability.\n\nLet $H$ be the event that the patient has HIT type II.\nLet $\\neg H$ be the event that the patient does not have HIT type II.\nLet $E$ be the event that the ELISA test is positive.\n\nThe definition of conditional probability for two events $A$ and $B$ is given by:\n$$P(A|B) = \\frac{P(A \\cap B)}{P(B)}$$\nWe wish to find the post-test probability, which is $P(H|E)$. Using the definition:\n$$P(H|E) = \\frac{P(H \\cap E)}{P(E)}$$\nFrom the same definition, we can also write the probability of a positive test given the disease, $P(E|H)$, as:\n$$P(E|H) = \\frac{P(E \\cap H)}{P(H)}$$\nSince the intersection of events is commutative, $P(H \\cap E) = P(E \\cap H)$. We can rearrange the second equation to solve for this intersection:\n$$P(H \\cap E) = P(E|H) P(H)$$\nSubstituting this expression into our equation for $P(H|E)$ yields Bayes' theorem:\n$$P(H|E) = \\frac{P(E|H) P(H)}{P(E)}$$\nThe total probability of a positive test, $P(E)$, can be expressed using the law of total probability. A positive test can occur in two mutually exclusive scenarios: the patient has the disease and tests positive (a true positive), or the patient does not have the disease and tests positive (a false positive).\n$$P(E) = P(E \\cap H) + P(E \\cap \\neg H)$$\nUsing the definition of conditional probability again, this can be written as:\n$$P(E) = P(E|H) P(H) + P(E|\\neg H) P(\\neg H)$$\nSubstituting this expanded form for $P(E)$ into Bayes' theorem gives the full equation needed for our calculation:\n$$P(H|E) = \\frac{P(E|H) P(H)}{P(E|H) P(H) + P(E|\\neg H) P(\\neg H)}$$\n\nNow, we must identify the given values from the problem statement:\n- The pre-test probability of HIT type II is $P(H) = 0.20$.\n- The probability of not having HIT type II is therefore $P(\\neg H) = 1 - P(H) = 1 - 0.20 = 0.80$.\n- The sensitivity of the ELISA is the probability of a positive test given that the patient has the disease: $P(E|H) = 0.97$.\n- The specificity of the ELISA is the probability of a negative test given that the patient does not have the disease: $P(\\neg E|\\neg H) = 0.80$.\n\nWe need the term $P(E|\\neg H)$, which is the false positive rate. This is the complement of the specificity (the true negative rate), as for a patient without the disease, the test can only be negative or positive.\n$$P(E|\\neg H) = 1 - P(\\neg E|\\neg H) = 1 - 0.80 = 0.20$$\n\nNow we substitute all the numerical values into the full Bayes' theorem equation:\n$$P(H|E) = \\frac{(0.97)(0.20)}{(0.97)(0.20) + (0.20)(0.80)}$$\nFirst, we calculate the numerator and the terms in the denominator:\nNumerator: $0.97 \\times 0.20 = 0.194$\nDenominator, first term: $0.97 \\times 0.20 = 0.194$\nDenominator, second term: $0.20 \\times 0.80 = 0.160$\nThe total denominator is $0.194 + 0.160 = 0.354$.\n\nNow we compute the final probability:\n$$P(H|E) = \\frac{0.194}{0.354}$$\n$$P(H|E) \\approx 0.54802259...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$P(H|E) \\approx 0.5480$$\nThis is the post-test probability that the patient has HIT type II given the positive ELISA result.", "answer": "$$\\boxed{0.5480}$$", "id": "4995652"}]}